Advertising Therapeutic Goods in Australia

The Therapeutic Goods Administration (TGA) published new guidance on advertising of therapeutic goods, which came into force on 1st Jan 2019.

Website and Social Media Traps

If you’re advertising therapeutic goods in Australia in 2019, there’s new legislation that is critical to your successful campaign/s.

We’ve been keeping up to date over the break to ensure we’re ready to assist our clients with all of their commercialisation needs around the globe.

New Guidelines Released by Therapeutic Goods Administration (TGA)

The Therapeutic Goods Administration (TGA) published new guidance on advertising of therapeutic goods, which came into force on 1st Jan 2019.

When advertising therapeutic goods to the public, advertisers must comply with the  Therapeutic Goods Advertising Code (No 2) 2018 (Repealed on 01 January 2022 by s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021) . Not all therapeutic goods are allowed to be advertised to the public. Some examples include biologicals and goods made available solely on prescription from a registered healthcare provider (for example a doctor or dentist). This is not an exhaustive list.

The definition of advertising includes websites and social media. TGA has now included these forms of advertising specifically in their guidance.

As there are penalties for non-compliance, it’s important for international companies to understand the differences in advertising rules in Australia and to seek expert local advice. In many cases, we can suggest alternative ways of getting your message across, without contravening the Therapeutic Goods Act and the Advertising Code.

In November 2018, TGA began legal proceedings against Peptide Clinics Pty Ltd for a raft of alleged breaches. This is a cautionary tale, the details of which, can be a found here:  TGA takes aim at Peptides Clinics Australia for alleged advertising breaches.

Being effective and in compliance in your advertising will mean that you are not the subject of this type of negative press and legal expenses, give you the edge over your competitors and make sure you’re maximising the returns from your advertising spend.

2024: Recent Changes: Advertising cosmetic injectables

TGA recently updated its guidance on advertising cosmetic injectables to ensure consistency across all industries handling therapeutic goods.

Contact us today and let’s work together to achieve your goals. Whether you have a question, need more information, or want to discuss your project, our team is here to help.

More recent articles

  • Regulation of In Vivo CAR‑T Therapies

    Regulation of In Vivo CAR‑T Therapies

    Emerging Regulatory Frameworks for Programmable Immune Engineering Introduction In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology. Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the…

  • From Sequential to Strategic

    From Sequential to Strategic

    How Smart Biotech Companies Are Winning in Accelerated Global Approval Pathways The global biotechnology regulatory environment is no longer just accelerating, it is fragmenting into a set of strategic choices that materially impact time to market, capital efficiency, and valuation. Companies that actively design multi-market regulatory strategies early are gaining measurable advantages. Those that don’t…

  • Orphan and Rare Diseases in 2026

    Orphan and Rare Diseases in 2026

    How Australia Accelerates Global Development A Maturing Global Rare Disease Landscape. In rare diseases, time equals patient impact. Leveraging Australia’s advantages enables faster, smarter global development. What are Orphan and Rare Diseases? Orphan and rare diseases are conditions that affect a small percentage of the population, often defined as impacting fewer than 1 in 2,000…